Patent application number | Description | Published |
20100197005 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 08-05-2010 |
20100330078 | ALPHA 5 - BETA 1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 12-30-2010 |
20120009622 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 01-12-2012 |
20140154268 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 06-05-2014 |
Patent application number | Description | Published |
20090181389 | QUANTITATIVE MEASUREMENT OF NUCLEIC ACID VIA LIGATION-BASED LINEAR AMPLIFICATION - Methods, compositions and kits are provided for sensitive and quantitative detection of nucleic acid, especially for the determination of the presence and/or amount of a target nucleic acid with mutations or single nucleotide polymorphism (SNP). In particular, assays are provided for amplifying a target nucleic acid via ligation of designed oligonucleotide probes and linear amplification by using an RNA polymerase, such as T7 polymerase. The assays can be used for diagnosis, prognosis or monitoring of diseases or disorders, for pharmacogenomic studies of patient stratification and drug responses, for discovery of therapeutic targets, or for forensic analysis. | 07-16-2009 |
20090181390 | HIGH THROUGHPUT DETECTION OF MICRORNAS AND USE FOR DISEASE DIAGNOSIS - Methods, compositions and kits are provided for high throughput detection of micro RNAs (miRNA), especially for sensitive and specific detection of miRNA that are in low abundance and closely related to each other. In particular, an assembly of designed oligonucleotide probes with unique tag sequences is used to achieve these purposes via high throughput microarrays, optionally in conjunction with branched-DNA based array detection. The assays can be used for diagnosis, prognosis or monitoring of diseases or disorders such as cancer, for pharmacogenomic studies of patient stratification and drug responses, for discovery of therapeutic targets, or for forensic analysis. | 07-16-2009 |
20100304394 | Screening methods involving the detection of short-lived proteins - A method is provided for screening for agents that affect protein degradation rates, the method comprising: taking a library of cells, the cells expressing a fusion protein comprising a reporter protein and a protein encoded by a sequence from a cDNA library derived from a sample of cells, the sequence from the cDNA library varying within the cell library; contacting the library of cells with a plurality of agents which may affect protein degradation rates; for each agent, selecting cells in the library which express short-lived proteins based on whether the cells have different reporter signal intensities than other cells in the library, the difference being indicative of the selected cells expressing shorter lived fusion proteins than the fusion proteins expressed by the other cells in the library; and characterizing the fusion proteins expressed by the selected cells for each agent. | 12-02-2010 |
20120046200 | Screening Methods Involving the Detection of Short-Lived Proteins - A method is provided for screening for agents that affect protein degradation rates, the method comprising: taking a library of cells, the cells expressing a fusion protein comprising a reporter protein and a protein encoded by a sequence from a cDNA library derived from a sample of cells, the sequence from the cDNA library varying within the cell library; contacting the library of cells with a plurality of agents which may affect protein degradation rates; for each agent, selecting cells in the library which express short-lived proteins based on whether the cells have different reporter signal intensities than other cells in the library, the difference being indicative of the selected cells expressing shorter lived fusion proteins than the fusion proteins expressed by the other cells in the library; and characterizing the fusion proteins expressed by the selected cells for each agent. | 02-23-2012 |
Patent application number | Description | Published |
20090189712 | Spiral Coupler - An improved spiral coupler including a plurality of parallel, coextensive conductive strips disposed in a planar spiral path, including a first strip having an input port and a direct or through port, a second strip having a coupler port and an isolated port and a first cross-over connection for bridging the strips from the inside to the outside of the spiral path to provide all four the ports external access to the spiral path. | 07-30-2009 |
20100231316 | Hybrid marchand/back-wave balun and double balanced mixer using same - A hybrid Marchand/back-wave balun includes a first pair of coupled sections having a first primary section and first secondary section; a second pair of coupled sections having a second primary section and second secondary section; a first reactance interconnecting the first and second primary sections and a second reactance interconnecting the first and second secondary sections; one of the reactances being open at high frequency and shorted at low frequency, the other reactance being shorted at high frequency and open at low frequency for selectively providing low frequency Marchand/high frequency back-wave function and high frequency Marchand/low frequency back-wave function; and a double balanced mixer using same. | 09-16-2010 |
20110221505 | Distributed, diode mixer circuit - A distributed, diode mixer circuit includes a plurality of passive diode mixer cores including at least first and second passive diode mixer cores including doubly-balanced diodes in symmetrical balanced configuration forms, each mixer core having a pair of differential reference nodes driven by the reference signal and a pair of differential nodes driven by the data signal and a reactive impedance network including one or multiple reactive elements or transmission lines connected between the like nodes of each the first and second mixer cores. | 09-15-2011 |
20110312295 | Double balanced mixer - An improved double balanced mixer is provided which in one embodiment includes a first balun for receiving a first single input and providing a first balanced output having two ports, a second balun for receiving a second single input and providing a second balanced output having two ports, and a balanced mixer core responsive to the first and second balanced outputs to provide a mixed signal from the first and second single inputs. The first balun includes an RC network coupled between at least one of the ports of the first balanced output and one of ground and a common mode node of the first balun to improve the linearity of the double balanced mixer. | 12-22-2011 |
Patent application number | Description | Published |
20080249162 | PALMEROLIDES: METHODS OF PREPARATION AND DERIVATIVES THEREOF - Organic compounds having Formulas I and II are provided where the variables have the values described herein. | 10-09-2008 |
20100041904 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 02-18-2010 |
20100048887 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE - This invention provides novel compounds comprising the following anti-inflammatory pharmacore: | 02-25-2010 |
20100048892 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 02-25-2010 |
20100048911 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID - Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress. | 02-25-2010 |
20100056777 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 03-04-2010 |
20110245206 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 10-06-2011 |
20110245233 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 10-06-2011 |
20120214814 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO ACID AND OTHER MODIFICATIONS AT C-17 - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 08-23-2012 |
20120238767 | ANTIOXIDANT INFLAMMATION MODULATORS: NOVEL DERIVATIVES OF OLEANOLIC ACID - Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress. | 09-20-2012 |
20120245374 | Antioxidant Inflammation Modulators: Oleanolic Acid Derivatives with Saturation in the C-Ring - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 09-27-2012 |
20120283450 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE - This invention provides novel compounds comprising the following anti-inflammatory pharmacore: | 11-08-2012 |
20130317007 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 11-28-2013 |
20140066408 | ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 03-06-2014 |
20140179928 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING - This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: | 06-26-2014 |
Patent application number | Description | Published |
20120196880 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS - Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: | 08-02-2012 |
20120252776 | C4 Monomethyl Triterpenoid Derivatives and Methods of Use Thereof - Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula: | 10-04-2012 |
20140051739 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS - Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: | 02-20-2014 |
20140088163 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: | 03-27-2014 |
20140088188 | C13-HYDROXY DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula: | 03-27-2014 |
20140100227 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: | 04-10-2014 |
20140249120 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS - The present disclosure is generally directed to neuroactive 13,17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 09-04-2014 |